Xilio shares tumble after mixed vilastobart data

23 January 2025

Xilio Therapeutics (Nasdaq: XLO) has reported initial results from its Phase II trial of vilastobart, an anti-CTLA-4 therapy, in combination with Roche's (ROG: SIX) Tecentriq (atezolizumab).

The trial is testing the combo as an option for certain people with colorectal cancer. Presented at a meeting of the American Society of Clinical Oncology, the mixed results appeared to worry investors on Wednesday, sending shares down by around a third.

The trial involved 40 patients, 70% of whom had undergone at least three prior lines of anti-cancer therapy. One positive sign was an objective response rate (ORR) of 27% from a subset of patients, including three partial responses.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology